Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

CytoMed Therapeutics Limited

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SINGAPORE, OCT. 02, 2025 (GLOBE NEWSWIRE) -- CYTOMED THERAPEUTICS LIMITED (NASDAQ: GDTC) (CYTOMED OR COMPANY), A SINGAPORE-BASED CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING ITS PROPRIETARY TECHNOLOGIES TO DEVELOP NOVEL AFFORDABLE DONOR-DERIVED CELL-BASED IMMUNOTHERAPIES FOR THE TREATMENT OF A BROAD RANGE OF CANCERS, INCLUDING BOTH BLOOD AND SOLID TUMOURS, IS PLEASED TO ANNOUNCE THE PUBLICATION OF A PRECLINICAL STUDY, IN A RESEARCH ARTICLE ENTITLED DONOR-DERIVED V9V2 T CELLS FOR ACUTE MYELOID LEUKEMIA: A PROMISING OFF-THE-SHELF IMMUNOTHERAPY APPROACH. THE STUDY RESULTS FROM THIS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF TEXAS, MD ANDERSON CANCER CENTER (MDACC), ARE SUGGESTING THE PROMISING POTENTIAL OF CYTOMED'S ALLOGENEIC  T CELL THERAPY (CTM-GDT) FOR TREATING ACUTE MYELOID LEUKEMIA (AML). THIS COLLABORATION WITH MDACC IS UNDER A PREVIOUSLY ANNOUNCED RESEARCH AGREEMENT IN MAY 2023. THE RESEARCH ARTICLE IS NOW PUBLICLY AND FREELY ONLINE AT DONOR-DERIVED V9V2 T CELLS FOR ACUTE MYELOID LEUKEMIA: A PROMISING OFF-THE-SHELF IMMUNOTHERAPY APPROACH.

CYTOMED THERAPEUTICS ANNOUNCES PUBLICATION OF COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF TEXAS, MD ANDERSON CANCER CENTER, DEMONSTRATING THE POTENTIAL OF ALLOGENEIC  T CELLS IN ACUTE MYELOID LEUKEMIA

SINGAPORE, AUG. 28, 2025 (GLOBE NEWSWIRE) -- CYTOMED THERAPEUTICS LIMITED (NASDAQ: GDTC) (CYTOMED OR COMPANY), A SINGAPORE-BASED CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING ITS PROPRIETARY TECHNOLOGIES TO DEVELOP NOVEL AFFORDABLE DONOR-DERIVED CELL-BASED IMMUNOTHERAPIES FOR THE TREATMENT OF A BROAD RANGE OF CANCERS, INCLUDING BOTH BLOOD AND SOLID TUMOURS, IS PLEASED TO ANNOUNCE IT HAS SUCCESSFULLY EXPANDED CLINICAL-SCALE NATURAL KILLER (NK) CELLS FROM CORD BLOOD UNITS THAT HAVE BEEN CRYOPRESERVED FOR MORE THAN A DECADE. THIS SETS THE IMPETUS FOR ESTABLISHING A NEW BUSINESS PLATFORM TO GENERATE ADDITIONAL REVENUE STREAMS AND FUTURE GROWTH.

UPDATE ON RECENT ACQUISITION - CYTOMED THERAPEUTICS EXPANDS INTO AUTO-IMMUNE DISEASES BUILDING ON ITS RECENT CORD BLOOD BANK ACQUISITION

SINGAPORE, AUG. 18, 2025 (GLOBE NEWSWIRE) -- CYTOMED THERAPEUTICS LIMITED (NASDAQ: GDTC) (CYTOMED OR COMPANY), A SINGAPORE-BASED CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING ITS PROPRIETARY TECHNOLOGIES TO DEVELOP NOVEL DONOR BLOOD-DERIVED, CELL-BASED ALLOGENEIC THERAPIES FOR THE AFFORDABLE TREATMENT OF BLOOD AND SOLID CANCERS, IS PLEASED TO ANNOUNCE THAT IT ENTERED INTO AN AT-THE-MARKET SALES AGREEMENT (THE SALES AGREEMENT) WITH R.F. LAFFERTY & CO., INC. (THE AGENT), AS THE SALES AGENT.

CYTOMED THERAPEUTICS LIMITED ANNOUNCES AT-THE-MARKET (ATM) OFFERING PROGRAM

SINGAPORE, JULY 21, 2025 (GLOBE NEWSWIRE) -- FURTHER TO OUR ANNOUNCEMENT FILED ON FORM 6-K ON NOVEMBER 20, 2024, CYTOMED THERAPEUTICS LIMITED (NASDAQ: GDTC) (CYTOMED OR COMPANY), A SINGAPORE-BASED CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING ITS PROPRIETARY TECHNOLOGIES TO DEVELOP NOVEL DONOR BLOOD-DERIVED, CELL-BASED ALLOGENEIC THERAPIES FOR THE AFFORDABLE TREATMENT OF BLOOD AND SOLID CANCERS, IS PLEASED TO ANNOUNCE THE SUCCESSFUL COMPLETION OF DOSE LEVEL 1 FOR ITS FIRST-IN-HUMAN PHASE I DOSE-ESCALATION CLINICAL TRIAL (NCT05302037) (ANGELICA TRIAL) FOR FOUR LATE STAGE CANCER PATIENTS AND IS SCHEDULED TO START DOSE LEVEL 2 OF THE ANGELICA TRIAL IN THIRD QUARTER OF 2025.

UPDATE ON CLINICAL TRIAL MILESTONE - CYTOMED THERAPEUTICS ACHIEVES COMPLETION OF DOSE LEVEL 1 OF ITS ANGELICA TRIAL, AND PROCEEDING TO DOSE LEVEL 2 IN PATIENTS WITH ADVANCED SOLID TUMORS OR HAEMATOLOGICAL MALIGNANCIES

SINGAPORE, APRIL 28, 2025 (GLOBE NEWSWIRE) -- CYTOMED THERAPEUTICS LIMITED(NASDAQ: GDTC) (CYTOMED OR THE COMPANY), A SINGAPORE-BASED CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING ITS PROPRIETARY TECHNOLOGIES TO DEVELOP NOVEL AFFORDABLE DONOR-DERIVED, CELL-BASED ALLOGENEIC IMMUNOTHERAPIES WITHOUT ENGAGING IN SEPARATE ACTIVITIES SUCH AS CONTRACT MANUFACTURING, CONTRACT RESEARCH, MEDICAL DEVICE DEVELOPMENT, OR DIAGNOSTICS, TODAY ANNOUNCED ITS FULL-YEAR ENDED DECEMBER 31, 2024 FINANCIAL RESULTS AND PROVIDED CLINICAL AND CORPORATE UPDATES.

CYTOMED THERAPEUTICS REPORTS FULL YEAR ENDED DECEMBER 31, 2024 FINANCIAL RESULTSAND PROVIDES CLINICAL AND CORPORATE UPDATES

SINGAPORE, FEB. 06, 2025 (GLOBE NEWSWIRE) -- CYTOMED THERAPEUTICS LIMITED (NASDAQ: GDTC) (CYTOMED OR THE COMPANY) TODAY RELEASED A LETTER TO SHAREHOLDERS FROM THE CHAIRMAN OF THE COMPANY'S BOARD OF DIRECTORS (THE BOARD) AS IT WELCOMES THE NEW YEAR AHEAD OF ITS FULL-YEAR AUDITED RESULTS ANNOUNCEMENT DUE BY END-APRIL, THE FULL TEXT OF WHICH IS PROVIDED BELOW. ALL SHAREHOLDERS OF CYTOMED ARE ENCOURAGED TO READ.

CYTOMED THERAPEUTICS ANNOUNCES CHAIRMAN'S LETTER TO THE COMPANY'S SHAREHOLDERS

ANOTHER PATENT GRANTED FOR CYTOMED'S ALLOGENEIC INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED HYBRID GAMMA DELTA NATURAL KILLER T ( NKT) CELLS TECHNOLOGY ANOTHER PATENT GRANTED FOR CYTOMED'S ALLOGENEIC INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED HYBRID GAMMA DELTA NATURAL KILLER T ( NKT) CELLS TECHNOLOGY

CYTOMED THERAPEUTICS ACQUIRES CORD BLOOD BANKING LICENCE AND ASSETS TO ENTRENCH ITS STRATEGY IN ALLOGENEIC, OFF-THE-SHELF DONOR-DERIVED GAMMA DELTA () T CELLS TECHNOLOGY FOR SOLID AND LIQUID CANCERS

SINGAPORE / ACCESSWIRE / MARCH 20, 2024 / CYTOMED THERAPEUTICS LIMITED (NASDAQ:GDTC) ("CYTOMED" OR "THE COMPANY"), A SINGAPORE BIOPHARMACEUTICAL COMPANY THAT FOCUSES ON UTILIZING ITS LICENSED PROPRIETARY TECHNOLOGIES TO CREATE NOVEL ALLOGENEIC CELL-BASED IMMUNOTHERAPIES FOR TREATING A RANGE OF CANCERS, RECENTLY ANNOUNCED THAT IT HAS ENTERED INTO A RESEARCH COLLABORATION AGREEMENT WITH SENGKANG GENERAL HOSPITAL PTE LTD., A PUBLIC HOSPITAL IN SINGAPORE AND A MEMBER OF THE SINGHEALTH GROUP.

CYTOMED DIVERSIFIES INTO REGENERATIVE MEDICINE AFTER RESEARCH COLLABORATION WITH SINGAPORE'S SENGKANG GENERAL HOSPITAL TO TEST INJECTABLE UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS FOR CARTILAGE REGENERATION

SINGAPORE, MARCH 18, 2024 (GLOBE NEWSWIRE) -- CYTOMED THERAPEUTICS LIMITED (NASDAQ: GDTC) (CYTOMED OR COMPANY), A SINGAPORE-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING ITS PROPRIETARY TECHNOLOGIES TO DEVELOP NOVEL BLOOD DONOR-DERIVED, CELL-BASED ALLOGENEIC THERAPIES FOR THE TREATMENT OF VARIOUS CANCERS AND AGING-RELATED DISEASES, HAS OBTAINED BOARD APPROVAL TO LAUNCH, SUBJECT TO CERTAIN TERMS AND CONDITIONS, A PILOT PROGRAM (PROGRAM) TO ISOLATE AND CRYO-STORE PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) FOR AND AS A REWARD TO LOYAL SHAREHOLDERS OF CYTOMED ON A COMPLIMENTARY BASIS. THIS PROGRAM IS IN LINE WITH THE COMPANY'S STRATEGY TO BUILD UP A PRIVATE BANK OF PBMC DONORS TO DEVELOP ALLOGENEIC OFF-THE-SHELF CELLULAR THERAPIES USING PRE-QUALIFIED HEALTHY DONOR BLOOD. THIS PROGRAM WILL COMMENCE ON JUNE 1, 2024, OR AT SUCH OTHER DATE AS CYTOMED SHALL PROVIDE. INTERESTED SHAREHOLDERS ARE ADVISED TO REFER TO CYTOMED'S WEBSITE FOR ANY FUTURE UPDATES REGARDING THE PROGRAM.

CYTOMED THERAPEUTICS TO LAUNCH COMPLIMENTARY CELL BANKING FOR QUALIFIED SHAREHOLDERS FORFUTURE PRECISION THERAPIES

SINGAPORE, MARCH 04, 2024 (GLOBE NEWSWIRE) -- CYTOMED THERAPEUTICS LIMITED (NASDAQ: GDTC) (CYTOMED OR COMPANY), A SINGAPORE-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON HARNESSING ITS PROPRIETARY TECHNOLOGIES TO DEVELOP NOVEL DONOR-DERIVED CELL-BASED ALLOGENEIC THERAPIES FOR THE TREATMENT OF VARIOUS CANCERS AND AGING-RELATED DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A RESEARCH COLLABORATION AGREEMENT (RCA) WITH SENGKANG GENERAL HOSPITAL PTE LTD (SKH), A PUBLIC HOSPITAL IN SINGAPORE AND A MEMBER OF THE SINGHEALTH GROUP TO ESTABLISH PROOF-OF-CONCEPT USE OF AN INJECTABLE CARTILAGE REGENERATION THERAPY THAT HAS BEEN DEVELOPED WITH DONOR-SOURCED, (ALLOGENEIC) UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCS) TO TREAT CARTILAGE INJURY. THIS INJECTABLE THERAPY WILL BE IMPLEMENTED IN VIVO TO SUPPORT THE APPLICATION AND COMMENCEMENT OF A PROPOSED PHASE 1 CLINICAL TRIAL IN SINGAPORE, AND IS ANTICIPATED TO COMPLETE WITHIN TWO YEARS.

CYTOMED THERAPEUTICS LIMITED ANNOUNCES RESEARCH COLLABORATION WITH SINGAPORE SENGKANG GENERAL HOSPITAL TO ADVANCE INJECTABLE UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS FOR CARTILAGE DISEASES AND REPAIR

CytoMed Therapeutics Limited

GDTC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CytoMed Therapeutics Limited

GDTC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

GDTC